Huntleigh Advisors Inc. Purchases New Stake in GRAIL, Inc. $GRAL

Huntleigh Advisors Inc. purchased a new stake in shares of GRAIL, Inc. (NASDAQ:GRAL) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 6,200 shares of the company’s stock, valued at approximately $367,000.

Other large investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its stake in GRAIL by 21.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 34,195 shares of the company’s stock valued at $1,758,000 after acquiring an additional 6,032 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of GRAIL in the second quarter valued at about $3,320,000. NWF Advisory Services Inc. bought a new position in shares of GRAIL during the second quarter valued at about $1,062,000. Legal Advantage Investments Inc. bought a new position in shares of GRAIL during the third quarter valued at about $1,242,000. Finally, Sheets Smith Investment Management purchased a new position in GRAIL during the third quarter worth about $1,689,000.

Analyst Ratings Changes

Several equities research analysts have commented on GRAL shares. Guggenheim upgraded shares of GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Wednesday, November 12th. UBS Group set a $75.00 price target on GRAIL in a research report on Friday, October 3rd. Morgan Stanley lifted their price target on GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group raised their target price on GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $97.50.

GRAIL Trading Down 0.2%

GRAIL stock opened at $101.07 on Thursday. The business’s 50 day simple moving average is $95.41 and its 200 day simple moving average is $66.76. GRAIL, Inc. has a 12 month low of $18.80 and a 12 month high of $115.76. The company has a market cap of $3.94 billion, a price-to-earnings ratio of -8.69 and a beta of 4.52.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $0.94. The firm had revenue of $36.19 million for the quarter, compared to analyst estimates of $33.83 million. GRAIL had a negative return on equity of 15.69% and a negative net margin of 286.43%. As a group, equities research analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.